Atria Investments Inc Acquires 20,760 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Atria Investments Inc boosted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 57.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 56,613 shares of the company’s stock after acquiring an additional 20,760 shares during the period. Atria Investments Inc’s holdings in Elanco Animal Health were worth $832,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after buying an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in Elanco Animal Health during the third quarter worth approximately $29,000. nVerses Capital LLC bought a new stake in shares of Elanco Animal Health during the second quarter worth approximately $32,000. ORG Partners LLC acquired a new position in shares of Elanco Animal Health in the second quarter valued at approximately $31,000. Finally, Quarry LP acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $40,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of “Hold” and an average price target of $17.14.

Insider Buying and Selling

In related news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 4.51 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Trading Down 3.8 %

ELAN opened at $13.45 on Tuesday. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of 33.63, a P/E/G ratio of 1.46 and a beta of 1.41. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a twelve month low of $11.40 and a twelve month high of $18.80. The company has a 50-day simple moving average of $13.79 and a 200 day simple moving average of $14.77.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business posted $0.18 EPS. The firm’s revenue for the quarter was down 3.6% on a year-over-year basis. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.